A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
10 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety, tolerability, and efficacy of the recombinant herpes simplex virus I, R130 in patients with relapsed/refractory ovarian cancer.
Ovarian Cancer|Peritoneal Carcinomatosis|Fallopian Tube Cancer
DRUG: Recombinant oncolytic herpes simplex virus type 1 (R130)
Adverse Events, All serious and non-serious adverse events that occur after enrollment through 7 (+14) days after the last administration of R130 will be recorded, Up to 6 months|Systemic immune response, Detection of increased systemic immune Response markers in sera,ascites and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS), Up to 6 months
Disease Assessment for Disease Control Rate, Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST, Every 10 weeks for 12 months|Disease Assessment for Duration of Response, Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST, Every 10 weeks for 12 months|Quality of Life Assessment, Evaluate with EORTC QLQ-C30, Every 6 weeks for 12 months
10 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety, tolerability, and efficacy of the recombinant herpes simplex virus I, R130 in patients with relapsed/refractory ovarian cancer.